OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
ISCO
International Stem Cell Corp.
Common Stock
0.15
0.01
7.14%
0.131 / 0.15 (5000 x 5000)
Real-Time Best Bid & Ask: 02:00pm 11/28/2025
Delayed (15 Min) Trade Data: 11:53am 11/28/2025
0.15
0.15 - 0.15
5,000
Market Cap calculated only for this class of securities.
1,120,614
Real-Time Level 2 Quote
Bid
Ask
MPID MPID | Bid Price Bid Price | Size Size | Time Time |
|---|---|---|---|
GTS Securities LLC | 0.131 | 5,000 | 06:59 |
VIRTU Americas LLC | 0.13 | 5,000 | 11/26 |
Citadel Securities | 0.122 | 6,000 | 09:30 |
CANACCORD GENUITY LLC. | 0.122 | 5,000 | 08:45 |
StoneX Financial Inc. | 0.122 | 5,000 | 12:30 |
MPID MPID | Ask Price Ask Price | Size Size | Time Time |
|---|---|---|---|
VIRTU Americas LLC | 0.15 | 5,000 | 11/26 |
G1 Execution Services, LLC | 0.1579 | 5,000 | 12:30 |
StoneX Financial Inc. | 0.175 | 5,000 | 12:30 |
GTS Securities LLC | 0.194 | 5,000 | 09/10 |
Citadel Securities | 0.197 | 14,300 | 09:30 |
Trade Data
Date Date | Timestamp Timestamp | Price Price | $ Change $ Change | Volume Volume |
|---|---|---|---|---|
| 11/28/2025 | 11:53:26 | 0.15 | 0.01 | 5,000 |
| 11/26/2025 | 14:25:14 | 0.14 | -0.02 | 200 |
| 11/26/2025 | 13:47:04 | 0.157 | 0.02 | 5,000 |
| 11/26/2025 | 13:47:04 | 0.141 | 0.00 | 5,000 |
| 11/26/2025 | 13:46:55 | 0.141 | -0.02 | 1,000 |
News
International Stem Cell Corporation Announces 2024 Fourth Quarter and Year-End ResultsAccesswire | 03/31/2025
International Stem Cell Corporation Announces 2021 Fourth Quarter and Year-End ResultsAccesswire | 03/30/2022
Company Description
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
Videos
This company has not added any videos
Venture Market
The Company Profile data was verified by the issuer within the previous 6 months.
This security is not a Penny Stock as defined in SEC Rule 240.3a51-1.
The company’s transfer agent has verified its outstanding shares directly to OTC Markets.
The Company’s board of directors includes at least two Independent Directors.
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.
Loading...
Symbol
OTCM
Last
51.77
Change
0.15 (0.29%)
Bid
51.60
Ask
51.77
Volume
3143
Time
11:59
© 2025 OTC Markets Group Inc.
Terms of ServiceLinking TermsTrademarksPrivacy StatementCode of ConductRisk WarningSupported Browsers